#United States #Kessler Topaz #Securities Fraud #Radnor #Zoetis Inc.

Legal Alert for Zoetis Inc. Investors

Investors in Zoetis Inc. (NYSE: ZTS) are being alerted about a significant securities fraud class-action lawsuit that has been initiated against the animal health company. This lawsuit pertains to individuals who acquired or purchased Zoetis securities between January 14, 2025, and May 6, 2026. If you fall into this category, it's crucial that you pay attention to this alert before the approaching July 27, 2026, deadline to file for lead plaintiff status.

Factual Background

On July 1, 2026, the law firm Kessler Topaz Meltzer & Check, LLP, a respected name in securities litigation, announced the lawsuit's filing in the U.S. District Court for the Southern District of New York. The case is officially titled City of Ann Arbor Retiree Health Care Benefit Plan Trust v. Zoetis Inc., under case number 26-cv-04401. Allegations within the lawsuit center around assertions that Zoetis and its representatives made materially false or misleading statements, which concealed essential information about the company's product adoption.

Key components of the lawsuit highlight concerns such as:
1. The weakening growth of prescription usage for Librela, a pain relief medication for dogs, following safety warnings from the FDA regarding neurological complications.
2. Significant market share loss for Simparica Trio, an antiparasitic drug, due to competition from a lower-priced alternative.
3. The decline in market share of Zoetis's dermatological products, specifically Apoquel and Cytopoint, against other competitors.
4. The resultant misleading character of the company's claims regarding its operational performance and future prospects.

Financial Impact on Investors

Zoetis experienced a stark decline in its stock value following the disclosure of its 2026 first-quarter financial results on May 7, which illustrated a substantial downturn in its Companion Animal business segment. Following this announcement, Zoetis's stock price plummeted by over 21%, highlighting the financial repercussions that such misleading information had on its investors.

Given these circumstances, affected investors are urged to take immediate action. By July 27, 2026, any investor who purchased ZTS securities during the class period can seek lead plaintiff status. This role allows the individual or group to represent all affected shareholders during the litigation process, facilitating the recovery of damages.

Next Steps for Investors

If you believe that your investments were adversely impacted by the alleged securities fraud, consider reaching out to Kessler Topaz Meltzer & Check, LLP. Interested parties can initiate contact through their website for further details on how to proceed, including obtaining a free case evaluation. It is important to note that representation by the firm operates on a contingency fee basis, meaning there are no upfront costs involved for legal services.

Take Action Now

In addition to reaching out to the law firm for assistance, affected investors should assess their options regarding participation in the case actively. Potential actions include:

• - Seeking lead plaintiff status through appropriate legal channels before the July deadline.
• - Retaining the counsel of your choice or choosing not to participate in the lawsuit.

About Kessler Topaz Meltzer & Check, LLP

Kessler Topaz Meltzer & Check, LLP is a distinguished U.S. law firm specializing in securities-fraud litigation and investor protection. The firm represents both individual and institutional investors, boasting a history of successful recoveries in high-profile securities cases. Investors can learn more about the firm and its services by visiting their official website.

In summary, if you have purchased or otherwise acquired Zoetis securities during the outlined timeframe and suffered financial losses, now is the critical time to act. Victims of the alleged fraud have a limited window to file claims and recover their investments. Contact Kessler Topaz Meltzer & Check, LLP for guidance on your legal rights and options moving forward.